



**Ref: JSTL/BOD/BSE/2025-26/AUG25**

**Date: August 14, 2025**

**To,  
The Manager  
BSE Limited  
P. J. Towers, Dalal Street  
Mumbai-400001  
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

**Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)**

**Sub: Copy of the Standalone and Consolidated Unaudited Financial Results for  
the Quarter Ended 30<sup>th</sup> June, 2025.**

Please find enclosed herewith a Copy of the Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30<sup>th</sup> June, 2025 which were taken on record by the Board of Directors at their Meeting held on 14<sup>th</sup> August, 2025.

This is for your information and records,

Thanking you,  
Yours truly,

**Jeevan Scientific Technology Limited**

**Krishna Sainadh Kodati  
Company Secretary & Compliance Officer**

Encl. As above

**Jeevan Scientific Technology Limited**

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June 2025**

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended		Year Ended	
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	Audited	Unaudited	Audited
<b>Revenue from operations</b>				
(a) Net sales/Income from operations	821.57	892.48	1,251.66	4,360.99
<b>I Total revenue from operation</b>	<b>821.57</b>	<b>892.48</b>	<b>1,251.66</b>	<b>4,360.99</b>
II Other Income	37.80	14.10	11.15	62.92
<b>III Total income (I+II)</b>	<b>859.37</b>	<b>906.58</b>	<b>1,262.81</b>	<b>4,423.90</b>
<b>IV Expenses</b>				
(a) Cost of materials consumed	62.27	112.19	94.87	365.10
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
(c) Employee benefits expense	421.47	461.46	365.19	1,565.30
(d) Finance costs	36.08	35.37	15.45	103.56
(e) Depreciation and Amortization expense	149.59	152.89	127.84	528.91
(f) Other Expenses	449.09	409.75	452.53	1,783.97
<b>Total Expenses (IV)</b>	<b>1,118.50</b>	<b>1,171.66</b>	<b>1,055.88</b>	<b>4,346.86</b>
<b>V Profit/ (Loss) before Tax (III-IV)</b>	<b>(259.13)</b>	<b>(265.08)</b>	<b>206.93</b>	<b>77.05</b>
<b>VI Tax Expenses</b>				
(a) Current tax	-	(41.35)	32.28	12.02
(b) MAT Credit / (Entitlement)	-	41.35	(32.28)	(12.02)
(c) Deferred tax	(43.14)	(131.37)	46.85	3.48
<b>Total tax expense</b>	<b>(43.14)</b>	<b>(131.37)</b>	<b>46.85</b>	<b>3.48</b>
<b>VII Profit(Loss) for the period/year (V-VI)</b>	<b>(215.99)</b>	<b>(133.71)</b>	<b>160.08</b>	<b>73.57</b>
<b>VIII Other Comprehensive Income</b>				
A (i) Items that will not be reclassified subsequently to profit or loss	-	2.46	-	(1.37)

  
  
**R. Venkateswar Rao**

	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total other comprehensive income/(loss) for the period</b>	-	2.46	-	-	(1.37)
IX	<b>Total Comprehensive income for the period (VII+VIII)</b>	(215.99)	(131.25)	160.08	72.20	
X	<b>Paid Up equity share capital (Face value of Rs. 10/- each)</b>	1,583.40	1,583.40	1,548.02	1,583.40	
XI	<b>Other equity</b>			-		3,508.41
XII	<b>Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)</b>					
	a) Basic	(1.36)	(0.86)	1.03	0.47	
	b) Diluted	(1.36)	(0.83)	1.03	0.46	

**Notes to the Unaudited financial results**

- The above Unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above Unaudited standalone results have been reviewed by the Audit Committee at its meeting held on 14th august, 2025 and approved by the Board of Directors of the Company at their meeting held on 14th august, 2025. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.
- Employee benefit expenses for the Quarter ending 30th June 2025 includes Rs. 12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
- The results for the Quarter ended 30th June 2025 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Place: Hyderabad.  
Date: 14th August, 2025

Krishna Kishore Kuchipudi  
Managing Director  
(DIN:00876539)



R. Venkateswara Rao  
Chief Financial Officer

**JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2025

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended			Year Ended
	30 June 2025 UnAudited	31 March 2025 Audited	30 June 2024 UnAudited	
<b>Revenue from operations</b>				
(a) Net sales/Income from operations	879.91	1,005.79	1,288.03	4,684.36
<b>Total revenue from operation</b>	<b>879.91</b>	<b>1,005.79</b>	<b>1,288.03</b>	<b>4,684.36</b>
Other Income	33.43	14.66	11.45	65.26
<b>III Total income (I+II)</b>	<b>913.34</b>	<b>1,020.45</b>	<b>1,299.48</b>	<b>4,749.62</b>
<b>IV Expenses</b>				
(a) Cost of materials consumed	77.33	115.38	99.11	380.25
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade			-	-
(c) Employee benefits expense	501.76	499.00	398.71	1,705.71
(d) Finance costs	53.91	54.60	33.20	176.09
(e) Depreciation and Amortization expense	174.03	177.08	151.39	625.16
(f) Other Expenses	479.29	429.69	467.64	1,857.34
<b>Total Expenses (IV)</b>	<b>1,286.32</b>	<b>1,275.75</b>	<b>1,150.05</b>	<b>4,744.55</b>
<b>V Profit/ (Loss) before tax (III-IV)</b>	<b>(372.97)</b>	<b>(255.30)</b>	<b>149.43</b>	<b>5.07</b>
<b>VI Tax expenses</b>				
(a) Current tax	-	(41.35)	32.28	12.02
(b) MAT Credit / (Entitlement)	-	41.35	(32.28)	(12.02)
(c) Deferred tax	(51.06)	(129.08)	46.81	(0.84)
<b>VIII Profit/(Loss) for the period/year</b>	<b>(321.91)</b>	<b>(126.22)</b>	<b>102.62</b>	<b>5.90</b>
<b>VIII Other Comprehensive Income</b>				
A (i) Items that will not be reclassified subsequently to profit or loss	-	2.46	-	(1.37)
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>IX Comprehensive Income for the period /year</b>	<b>-</b>	<b>2.46</b>	<b>-</b>	<b>(1.37)</b>
<b>Total Comprehensive Income for the period /year</b>	<b>(321.91)</b>	<b>(123.76)</b>	<b>102.62</b>	<b>4.53</b>



*R. Venkateshwar Rao*

X	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,583.40	1,583.40	1,548.02	1,583.40
XI	Other equity excluding revaluation reserve	-	-	-	3,410.97
XII	Earnings per Equity share	(2.03)	(0.81)	0.66	0.04
	a) Basic (Amount in Rupees)	(2.03)	(0.79)	0.66	0.04
	b) Diluted (Amount in Rupees)				
XIII	Net profit attributable to:	(310.15)	(129.91)	109.00	13.43
	Owners of the company	(11.76)	3.69	(6.38)	(7.53)
	Non-Controlling interest				
XIV	Other comprehensive income attributable to:	-	2.46	-	(1.37)
	Owners of the company	-	-	-	-
	Non-Controlling interest				
XV	Total comprehensive income attributable to:	(310.15)	(127.45)	109.00	12.06
	Owners of the company	(11.76)	3.69	(6.38)	(7.53)
	Non-Controlling interest				

**Notes to the Audited financial results**


- The above UnAudited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above UnAudited Consolidated results have been reviewed by the Audit Committee at its meeting held on 14th august, 2025 and approved by the Board of Directors of the Company at their meeting held on 14th august, 2025. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and issued unmodified conclusion.
- Employee benefit expenses for the Quarter ending 30th June 2025 includes Rs.12.02 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the Quarter ended 30th June 2025 are also available on website of BSE Limited and on the Company's website.

for Jeevan Scientific Technology Limited

Place: Hyderabad.  
Date: 14th August, 2025

Krishna Kishore Kutchipudi  
Managing Director  
(DIN:00876539)

*R. Venkateswara Rao*  
Venkateswara Rao Ravipati  
Chief Financial Officer  
HYDERABAD





Ref: JSTL/BOD/BSE/2025-26/AUG25

Date: August 14, 2025

**To,  
The Manager  
BSE Limited  
P. J. Towers, Dalal Street  
Mumbai-400001  
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

**Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)**

**Sub: Limited Review report of the Standalone and Consolidated Unaudited  
Financial Results for the Quarter Ended 30<sup>th</sup> June, 2025.**

We are herewith enclosing the Limited Review Report of the Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30<sup>th</sup> June, 2025 issued by our Statutory Auditors which were taken on record by the Board of Directors at their Meeting held on the 14<sup>th</sup> August, 2025.

This is for your information and records,

Thanking you,  
Yours truly,

**Jeevan Scientific Technology Limited**

**Krishna Sainadh Kodati  
Company Secretary & Compliance Officer**

Encl. As above



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE  
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pavuluri & Co  
Chartered Accountants  
FRN : 012194s  
  
CA. N. Rajesh  
Partner  
M.No : 223169



Place : Hyderabad  
Date : 14/08/2025

UDIN # 25223169BMILNU2381



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED  
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiary together referred to as "Group"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The consolidated unaudited financial results include the interim financial results of subsidiary company M/s Nayas Laboratories Private Limited. These unaudited financial results and other unaudited financial information have been furnished to us by the management and have been reviewed by us.
5. Based on our review conducted as stated in paragraph 3 above and based on the consideration of the review by us referred in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





**PAVULURI & Co.**  
CHARTERED ACCOUNTANTS  
Plot No.48, Flat No.301,  
MICASA, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639  
Email : mail@pavuluriandco.com

6. We have reviewed the interim financial information of the subsidiary M/s Nayas Laboratories Private Limited included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs 61.35 lakhs for the quarter ended June 30, 2025 total net loss after tax of Rs 105.92 lakhs for the quarter ended June 30, 2025 and total comprehensive loss of Rs 105.92 lakhs for the quarter ended June 30, 2025, as considered in the statement. This interim financial information has been reviewed by us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based on the review done by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

For Pavuluri & Co  
Chartered Accountants  
FRN : 012194s  
  
CA.N.Rajesh  
Partner  
M.No : 223169



Place : Hyderabad  
Date :14/08/2025

UDIN # 25223169BMILNV6591